Recruiting

Caffeine

Sponsor:

Wills Eye

Code:

NCT03675412

Conditions

Glaucoma, Primary Open Angle

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Caffeine tablet

Study Details

Brief summary:

Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various organs and the vascular system. It decreases ocular blood flow due to vasoconstriction.

Conditions

Glaucoma, Primary Open Angle

Study ID

NCT03675412

Start date

Dec 30, 2018

Status verified date

Aug, 2026

Completion date

Jun 30, 2027

Anticipated

Primary completion date

Apr 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • age 18 to 90 years
  • diagnosis of primary open angle glaucoma (Mild, Moderate and Advanced)
  • healthy subjects with no eye disease

Exclusion Criteria:

  • Diseases, ophthalmic or systemic, that are likely to affect OCTA results
  • greater than moderate cataract
  • nystagmus
  • inability to look at target
  • macular degeneration other than mild drusen or pigmentary changes
  • diabetic retinopathy
  • neovascular glaucoma or non-glaucoma optic neuropathies
  • current macular edema, prior laser to retina, inflammatory retinopathy or choroidopathy
  • keratoconus, corneal ectasia, central corneal scarring
  • rheumatologic diseases or Raynaud's phenomena
  • pregnant and lactating women
  • mental illness or alcohol addiction
  • pre-existing bladder symptoms, cardiac disease or sleep disorder
  • refractive spherical diopter greater than 5 or cylinder greater than 3
  • possible tolerance to caffeine (drinking more than 1 cup coffee per day).

Study Design

Enrollment

80 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

active comparator: Glaucoma Patients

Eligible participants include patients with mild, moderate or advanced primary open angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.

active comparator: Healthy controls

Eligible participants include healthy subjects with no eye diseases. Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.

Interventions

Caffeine tablet

Each eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.

Primary outcome measure

  • Blood flow change in back of eye before and after caffeine [ Time Frame: Baseline, Hour 1, Hour 2 ]

Central Contacts and Locations

Central contacts

M. Reza Razeghinejad, MD

215-928-7023mrazeghi@willseye.org

Jeanne Molineaux, COA

215-825-4713jmolineaux@gwillseye.org

Locations

Wills Eye Glaucoma Service

Recruiting

Philadelphia, Pennsylvania, United States, 19107

Contacts

Jeanne Molineaux, COA

215-825-4713jmolineaux@willseye.org

More Information

Sponsor

Wills Eye

Last update posted

Aug 20, 2026

Last verified

Aug, 2026

Keywords

  • Primary Open Angle Glaucoma (POAG)
  • Optical Coherence Tomography Angiography (OCTA)
  • Caffeine
  • Macular Blood Flow
  • Peripapillary Blood Flow

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Wills Eye on 2026-08-20.